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Abstract
Semliki Forest virus (SFV) vectors have been applied for the expression of recombinant integral membrane proteins in a wide range of
mammalian host cells. More than 50 G protein-coupled receptors (GPCRs), several ion channels and other types of transmembrane or
membrane-associated proteins have been expressed at high levels. The establishment of large-scale SFV technology has facilitated the
production of large quantities of recombinant receptors, which have then been subjected to drug screening programs and structure–function
studies on purified receptors. The recent Membrane Protein Network (MePNet) structural genomics initiative, where 100 GPCRs are
overexpressed from SFV vectors, will further provide new methods and technologies for expression, solubilization, purification and
crystallization of GPCRs.
D 2003 Elsevier Science B.V. All rights reserved.
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1. Introduction
The completion of the draft sequence of the human
genome has generated vast amounts of sequence infor-
mation, which awaits further analysis to enhance the
understanding of the function of individual genes and
proteins, and their interactions. Although sophisticated
bioinformatics programs have been developed, it is
essential to study the function of these sequences in vivo
by recombinant protein overexpression approaches. The
development of efficient expression systems has, there-
fore, been essential.
During the past 10 years, a multitude of expression
vectors and host cell systems have been engineered, span-
ning from simple prokaryotic vectors to complicated
eukaryotic expression methods. Obviously, bacterial expres-
sion systems, especially those based on Escherichia coli
vectors, have been used frequently. However, these have
turned out to be less suitable for overexpression of mamma-
lian transmembrane proteins. The main reason for this is the
many post-translational modifications and processing events
required for correct folding of mammalian proteins, which
prokaryotic cells lack. Additionally, insertion of recombi-
nantly expressed mammalian membrane proteins into bac-
terial membranes has caused severe toxicity to the host cells.
Alternatively, overexpressed transmembrane proteins can be
guided to form inclusion bodies in E. coli. The drawback of
this approach is that extensive and difficult refolding exer-
cises are required to restore the function of the recombinant
receptors. Archaebacteria, such as Halobacterium salina-
rum, have been developed as expression vectors for heter-
ologous proteins [1]. Because H. salinarum naturally
expresses large quantities of bacteriorhodopsin, it was
thought that also mammalian transmembrane proteins could
be well expressed in this organism. Disappointingly, even
fusions between bacteriorhodopsin and mammalian trans-
membrane receptors resulted in only modest expression
levels [2]. Other types of expression systems that have
received increasing attention are those based on yeast cells.
Saccharomyces cerevisiae has proven useful for expression
of some transmembrane receptors although the glycosyla-
tion pattern is quite different from the one seen in mamma-
lian cells [3]. Application of Schizosaccharomyces pombe as
a host has brought vectors with a higher resemblance to
mammalian glycosylation modes [4]. Moreover, expression
of several G protein-coupled receptors (GPCRs) from
Pichia pastoris has been highly successful [5]. Other
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expression systems frequently used for transmembrane
proteins are based on Baculovirus vectors in insect cells [6].
Many attempts have also been carried out to develop
mammalian expression systems, which possess the capacity
of proper folding and processing of mammalian proteins.
However, many of the transient and stable expression
systems engineered have not lived up to the expectations.
Typically, conventional stable cell lines are time-consuming
to establish and the expression levels are modest. Further-
more, stability problems occur frequently, because the gene
expression cassette integrated into the host cell genome is
inactivated or deleted. Although the expression levels are
higher for transient systems, the gene delivery efficacy
varies from one cell line to another and especially large-
scale applications requiring suspension cultures are ineffi-
cient. In contrast, viral vectors possess some attractive
features such as the high efficiency of gene delivery to
many different mammalian host cell lines and the use of
generally very strong promoters responsible for high trans-
gene expression levels. Naturally, the drawback with viral
vectors is their potential biosafety risks.
This review focuses on the use of Semliki Forest virus
(SFV) vectors although similar expression systems have been
engineered for other alphaviruses such as Sindbis virus [7]
and Venezuelan Equine Encephalitis virus [8]. The major
issue described here is the application of SFV vectors for
overexpression of transmembrane proteins. Various exam-
ples are given of applications for structural and functional
studies based on the production of large quantities of
recombinant receptors in mammalian suspension cell cul-
tures. Furthermore, SFV vectors can be used for several other
applications not described in this review, such as for various
neurobiological studies, vaccine production and gene therapy
applications which are reviewed elsewhere [9,10].
2. SFV expression vectors
SFV is a single-stranded RNA virus with an envelope
structure. The SFV genome has been introduced into two
plasmid vectors as cDNA copies [11] (Fig. 1). The expression
vector contains the SFV nonstructural genes (nsP1-4), the
strong subgenomic SFV 26S promoter and a multilinker
cloning region for the introduction of foreign genes of
interest. The SFV structural proteins are provided from the
helper vector containing the capsid and envelope protein
genes. Co-transfection of in vitro transcribed recombinant
and helper RNA into BHK cells generates high-titer (109–
1010 infectious particles/ml) recombinant SFV particles.
These particles are capable of infecting a broad range of
Fig. 1. Schematic illustration of the production of replication-deficient SFV particles. Recombinant and helper RNAs are in vitro transcribed from
corresponding linearized DNA plasmids. BHK cells are co-electroporated and recombinant SFV particles harvested. Generated particles can be used for
infection of various cell lines and primary cell cultures to produce high-level recombinant protein expression.
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mammalian and other cell lines (amphibian, reptilian, insect,
avian and fish) as well as primary cells. However, due to the
presence of the RNA packaging signal only in the recombi-
nant RNA, no helper RNA will be packaged, which renders
the generated particles replication deficient. Upon infection
of host cells, rapid and high-level transgene expression is
obtained from SFV vectors without the generation of virus
progeny.
Typically, recombinant SFV particles can infect many
mammalian host cell lines generally used for the expression
of recombinant proteins [12]. One advantage of using SFV
is the possibility to perform expression studies in several
cell lines in parallel. Moreover, cell types which natively
express the gene of interest can be subjected to SFV
infections and the feasibility of gene delivery and expres-
sion capacity can initially be evaluated by reporter gene (h-
galactosidase, GFP) expression. Topologically different
proteins have been successfully expressed from SFV vec-
tors. For instance, cytoplasmic expression of bacterial h-
galactosidase resulted in yields of 109 molecules per cell and
the recombinant protein represented approximately 25% of
the total cellular protein yields. Other intracellular proteins,
which have resulted in high expression levels, are dehy-
drofolate reductase [11], thyroid peroxidase [13] and UDP-
gluconoryltransferase [14]. Also a few secretory proteins
have been expressed, such as plasminogen activator inhib-
itor (PAI) [15], interleukin-12 [16] and secreted alkaline
phosphate [17]. Additionally, high level of enzyme activity
was obtained for human cyclooxygenase 2 (COX-2), which
resides in microsomal membranes as a membrane-associ-
ated enzyme [18].
3. G protein-coupled receptors
Probably the largest group of transmembrane proteins
expressed from SFV vectors has been the GPCRs. GPCRs
are the major targets for drug development today, on which
a quarter of the current top 200 drugs are based [19]. The
seven-transmembrane topology of GPCRs has generally
made it difficult to obtain high expression levels in various
expression systems. In fact, the low expression yields
obtained have constituted a significant bottleneck for both
drug screening activities and structural studies. In contrast,
SFV with its high RNA replication capacity and its strong
subgenomic promoter has favored high-level GPCR expres-
sion. Furthermore, the broad host range of SFV has sig-
nificantly facilitated the choice of host cells to be applied for
Table 1
SFV-based expression of membrane proteins
Membrane protein Host cell Function Expression level Ref.
Transferrin receptor BHK single transmembrane 5–10% of membrane prot. [11]
Serotonin 5-HT3 receptor BHK, CHO, neurons ligand-gated ion channel 60 pmol/mg; 2 mg/l [27,29]
Purinoreceptor P2X1, 2, 4 BHK, CHO ligand-gated ion channel 70–150 pmol/mg [28]
Adenosine A1, A2a, A2b BHK, CHO GPCR 20–50 pmol/mg; 2 mg/l [17]
A3 BHK, CHO GPCR 1 pmol/mg [51]
Adrenergic a1b, a2b, h2 BHK, COS GPCR 40–200 pmol/mg; 5 mg/l [26]
Cannabinoid R1 BHK, CHO GPCR 20 pmol/mg [17]
Chemokine CCK-1, CCK-2 BHK GPCR 300,000 receptors/cell [17]
Dopamine D2, D3, D4 BHK, CHO, HOS GPCR 20–50 pmol/mg [39]
Endothelin A, B BHK, COS GPCR 20 pmol/mg [52]
Galanin R1, R2, R3 BHK, CHO GPCR 20–50 pmol/mg [17]
Histamine H1 and H2 receptors CHO, COS GPCR 50–100 pmol/mg [47]
Interleukin IL8A, IL8B BHK GPCR 120,000 receptors/cell [17]
Metabotropic mGluR1 BHK, CHO, neurons GPCR 120 pmol/mg; 3–6 mg/l [17]
2, 3, 4, 8 BHK, CHO, neurons GPCR 9–20 pmol/mg [48,49]
Neurokinin receptors 1, 2 BHK, CHO, HOS GPCR 40–100 pmol/mg; 10 mg/l [21,25]
Olfactory receptors BHK, HEK293, OLF442 GPCR 10–20% of membrane prot. [22]
Opioid receptors y, n, A BHK, CHO, HEK293, C6 GPCR 20–50 pmol/mg; 1–3 mg/l [24]
Prostaglandin E2ep4 BHK, CHO GPCR 3 pmol/mg [53]
Serotonin 5-HT1, 6, 7 BHK, CHO, HEK293 GPCR 20–50 pmol/mg; 1–3 mg/l [50]
Dopamine transporter BHK transporter [3H] dopamine uptake only [34]
Cyclooxygenase 1, 2 BHK, CHO membrane-associated 4000 pg PGE2/Ag micros. prot. [18]
Catechol-o-methyltransferase BHK, neurons membrane-bound 10–20% of total prot. [32]
Presinilin 1, 2 BHK, neurons transmembrane protein localization studies only [54]
APP BHK, CHO, neurons amyloid precursor protein 20% of total prot. [55]
GABAA receptor BHK, neurons heteromeric channel 0.5–2 pmol/mg [30]
Potassium channel Kv 1.1, 1.2 CHO octomeric channel functional studies only [31]
Yeast syntaxin Sso2p BHK membrane insertion localization studies only [33]
G proteins: Gaq, Gh2, Gg2 BHK, COS membrane-associated functional coupling to GPCRs [46]
pmol/mg, picomoles of receptor expressed per milligram of membrane protein.
mg/l, milligrams of receptor per liter of cultured cells.
prot., protein.
micros., microsomal.
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specific receptor expression. Because the SFV vectors have
been subjected to large-scale production of recombinant
proteins in suspension cultures of mammalian cell lines, it
has allowed expression of large quantities of GPCRs.
Various types of GPCRs have been successfully expressed
from SFV vectors (Table 1). In general, the expression levels
obtained are much higher, often 10- to 100-fold higher than
achieved with many other systems. In this context, saturation
binding has demonstrated Bmax values of 50–150 pmol
receptor/mg protein for several GPCRs [20]. Binding assays
on intact BHK and CHO cells suggested receptor densities of
>3 106 receptors per cell [21]. SFV-based GPCR expres-
sion resulted in measurable coupling to G proteins, which
could be assayed for various receptors by intracellular Ca2 +
release, inositol phosphate accumulation, cAMP stimulation
and GTPgS binding [20]. Because of the high expression
levels obtained, it was reasonable to expect that not all
receptors are inserted into the plasma membrane. For
instance, localization studies of tagged olfactory receptors
indicated that not all receptors were transported to the cell
surface [22]. Similar observations were made for the human
neurokinin-1 receptor (NK1R), where a biotin tag was
engineered at the C terminus [17]. In this case, the biotin
tag was demonstrated not to interfere with the functional
activity of the NK1R measured by saturation binding and
coupling to G proteins (intracellular Ca2 + release) [23].
Moreover, the choice of host cells played a significant role,
because no signal was detected for olfactory receptors in the
plasma membrane of BHK cells, whereas strong receptor
expression was observed in the olfactory epithelial cell line
OLF442 and in primary hippocampal neurons on the cell
surface. Also, expression levels varied in different host cells.
For instance, the expression levels were 2- to 5-fold higher for
the rat n and A opioid receptors in rat C6 glioma cells
compared to BHK or CHO cells [24].
Generally, SFV-based expression has generated reason-
ably homogenous glycosylation of GPCRs based on SDS-
PAGE analysis. For instance, metabolic labeling with [35S]
methionine showed a single glycosylated form of NK1 [21]
and NK2 [25] receptors expressed in various host cell lines.
In contrast, overexpression of the hamster a1B adrenergic
receptor generated structural heterogeneity, which was due
to N-linked glycosylation and phosphorylation, but not
palmitoylation or O-linked glycosylation [26]. The hetero-
geneous glycosylation pattern was not a typical feature of
the high-level SFVexpression, but was also seen for the a1B
adrenergic receptor when other transient mammalian expres-
sion systems were applied.
4. Ion channels
In addition to GPCRs, ligand-gated ion channels have also
been efficiently expressed from SFV vectors (Table 1). The
mouse serotonin 5-HT3 receptor [27] and various rat and
human P2X purinoreceptors [28] demonstrated high binding
activity in several mammalian host cells. Moreover, func-
tional activity of P2X receptors was obtained by measuring
Ca2 + uptake in CHO cells after stimulation with ATP [29].
Additionally, the high infection rate of mammalian cells
allowed efficient patch-clamp recordings on whole cells
[27,28]. Overexpression of homopentameric ion channels,
such as the 5-HT3 receptor, has been shown to be fairly
straightforward. However, for channels that require the
assembly of several different subunits, it has turned out to
be more complicated to achieve high specific binding activ-
ity. For instance, assembly of functional GABAA receptors
required co-expression of at least a and h subunits both in
BHK cells and primary neurons [30]. It was demonstrated
that homomeric subunits were retained in the endoplasmic
reticulum, whereas heteromeric expression resulted in recep-
tor transport to the plasma membrane. In addition to ligand-
gated ion channels, potassium channels have also been
expressed from SFV vectors [31]. Functional assembly of
voltage-sensitive potassium channels from Kv1.1 or 1.2 a
subunits with either 1.1 or 1.2h subunits was demonstrated in
CHO-K1 cells co-infected with SFV vectors. Furthermore,
co-expression of His-tagged Kv a 1.2 and h 2.1 subunits
allowed purification of a 405-kDa complex, suggesting the
reconstruction of an octomeric structure.
5. Other transmembrane proteins
The feasibility of transmembrane protein expression from
SFV vectors was first demonstrated by overexpression of the
transferrin receptor in BHK cells [11]. The expression levels
were relatively high, although clearly lower than what had
been obtained for intracellular reporter proteins such as
bacterial h-galactosidase. Other membrane-inserted proteins,
such as catechol-o-methyltransferases (COMT), were
expressed from SFV vectors and the membrane localization
could be demonstrated in both BHK cells and primary
cultured superior cervical ganglion neurons [32]. Further-
more, the yeast syntaxin Sso2p demonstrated appropriate
insertion into the membrane of BHK cells after expression
from SFV vectors [33]. SFV-based expression of a dopamine
transporter was also conducted, although only by transfection
of in vitro transcribed RNA and not by infection with
recombinant SFV particles [34]. For this reason, the expres-
sion levels were moderate. The molecular mass of the
recombinant transporter was 56 kDa. Tunicamycin treatment
reduced the size to 50 kDa, which indicated that a proper
glycosylation pattern occurred. Moreover, the glycosylated
transporter was localized to the plasma membrane, whereas
the unglycosylated form was retained in the cytoplasm.
6. Large-scale production and purification
To facilitate the production of large quantities of
recombinant proteins in cells infected with SFV vectors,
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adaptation to growth in suspension cultures has been
established (Fig. 2). Several mammalian cell lines such
as BHK-21, CHO-K1, HEK293 and rat C6 glioma cells
were successfully cultured in serum-free medium. It was
demonstrated that the infection rates and expression levels
were comparable to what had earlier been achieved for
adherent cells [18]. Production of COX2 at 1 l scale in
BHK cells cultured in spinner flasks generated high
expression levels (16 mg COX2/l) with high specific
enzymatic activity (3942F 765 pg PGE2/microgram
microsomal protein/5 min) [18]. Interestingly, the culture
temperature had a significant effect on expression levels of
firefly luciferase in rodent cells, showing 10- to 20-fold
higher activity at 33 jC compared to 37 jC in BHK and
CHO cells [35]. In contrast, the luciferase activity was
only marginally higher in human HEK293 cells and no
differences were obtained in HEK293(EBNA) cells.
Recombinant protein production has also been carried out
in bioreactors. The mouse serotonin 5-HT3 receptor was
expressed in BHK cells cultured in 11.5 l volumes in
bioreactors [29]. A relatively high multiplicity of infection
(MOI) was used to enhance expression levels through multi-
ple infections as was earlier demonstrated for h-galactosidase
expression [18]. In fermentor cultures, the best results of
expression were obtained by performing SFV infections at
pH 6.9 for 2 h at 37 jC and then raising the pH to 7.4 for the
expression phase [36]. The BHK cells were harvested at 16–
18 h post infection, at which point saturation binding deter-
minations demonstrated 50–60 pmol receptor/mg protein,
equivalent to >3 106 receptors/cell. The production of
batches was highly reproducible with yields of the 5-HT3
receptor in the range of 1–2 mg/l culture.
In an attempt to further increase the expression levels of
the human NK1R, a fusion to the full-length SFV capsid
sequence was engineered. The capsid gene contains a trans-
lation enhancement signal at its 5V end, which is responsible
for 5- to 10-fold increase in expression levels [37]. More-
over, it was demonstrated that several recombinant proteins
were efficiently cleaved off by the autocatalytic cleavage
activity of the capsid. The capsid–NK1R fusion generated
5- to 10-fold higher expression levels compared to individ-
ually expressed NK1 receptor estimated from metabolic
labeling experiments, but also saturation binding assays
[21]. When the capsid–NK1R construct was subjected to
large-scale expression in spinner flasks, yields of 5–10 mg
receptor/l culture were achieved.
Fig. 2. Large-scale production in adherent cells and suspension cultures. Recombinant SFV particles are generated from plasmid DNA by in vitro transcription
of RNA and co-electroporations. Larger volumes of SFV particles are produced by electroporations in parallel cuvettes and/or larger cuvettes and co-culturing
in parallel T-flasks. Large-scale protein production can be performed in adherent cells in T-flasks or roller-bottles or in suspension cultures in spinner flasks or
bioreactors.
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7. Structural biology applications
The ease of engineering new SFV constructs and the
rapid virus production has also favored mutagenesis studies.
Site-directed mutagenesis and molecular modeling ap-
proaches have been combined to validate the involvement
of 11 amino acid residues in antagonist binding of the
human NK1 receptor [38]. Mutants Q165A, H197A and
F268A showed significantly reduced binding affinity for
some NK1 antagonists in CHO cells infected with recombi-
nant SFV–NK1R mutant particles. The results suggested
that all antagonists seemed to bind in a similar region of the
receptor, but did not rely on the same binding site inter-
actions. In another study, nine mutants and the wild-type
human dopamine D3 receptor were expressed in CHO cells
and analysed for binding properties with several structurally
different dopamine D3 ligands [39]. Sequence alignment
based on bacteriorhodopsin generated a model with amino
acid residues Thr369 and Leu349 located on the inside of
the binding pocket. The mutagenesis study revealed a
significant decrease for the His349Leu mutation in pKi
values for raclopride, dopamine and GR218231, but an
affinity increase for GR99841, whereas the Thr369Val
mutation showed an increase in pKi values for both
GR99841 and 7-OH-DPAT.
Production of tens of milligrams of receptor protein in
mammalian host cells has not only served drug screening
applications, but also studies in structural biology. Efficient
solubilization conditions were established for the overex-
pressed 5-HT3 receptor, where the detergent C12E9 showed
only minor effects on the receptor binding activity [40]. The
C-terminally hexa-histidine tagged receptor was subjected
to a one-step purification by metal ion affinity chromatog-
raphy and this resulted in visualization of a single band with
a mobility of 65 kDa in SDS-PAGE. Treatment with peptide
N-glycosidase F led to reduction of the molecular mass to 49
kDa, suggesting an appropriate glycosylation of the recom-
binantly expressed receptor. Size exclusion chromatography
was applied to determine the molecular mass of the func-
tional receptor complex of 280 kDa, which is in good
agreement with a pentameric structure. Dialyzed purified
receptor preparations were subjected to circular dichroism to
determine the secondary structure revealing mainly a-heli-
ces (50%) and h-strands (24%).
8. MePNet, structural genomics on GPCRs
Even though high expression levels of transmembrane
proteins have been achieved with the SFV system, there are
major obstacles before high-resolution structures can be
obtained. Much attention needs to be paid to improvements
in the areas of solubilization, purification, stabilization and
crystallization. However, the feasibility of GPCR crystalli-
zation was demonstrated recently by the successful deter-
mination of a high-resolution structure for bovine rhodopsin
[41], although this photoreceptor was isolated from bovine
retina and not expressed as a recombinant protein.
One approach to allow statistical analysis of the expres-
sion of a large number of GPCRs and also to develop
various technologies from expression to crystallization has
been the introduction of the Membrane Protein Network
(MePNet) structural genomics program [42]. MePNet is a
network consisting of four academic partners and is sup-
ported by more than 40 biotech and pharmaceutical com-
panies worldwide. The goal of the program is to overexpress
100 GPCRs in three expression systems based on E. coli, P.
pastoris and SFV vectors. The 30 best expressed GPCRs in
bacterial inclusion bodies will be subjected to refolding
exercises before purification attempts. In parallel, the 15
best overexpressed GPCRs in yeast and mammalian cell
membranes will be subjected to solubilization studies.
Successful refolding/solubilization will provide the basis
for future purification and crystallization attempts. This 3-
year research project aims at improving existing technolo-
gies, which already within this period might generate novel
high-resolution structures for GPCRs.
9. Conclusions and future aspects
SFV vectors have proven useful for the overexpression
of various integral transmembrane proteins. The rapid high-
titer virus production and broad host range have made these
vectors attractive for versatile applications in mammalian
cell lines and primary cell cultures. The high authenticity of
recombinantly expressed proteins is one of the most appre-
ciated assets of using SFV vectors. Large-scale production
of GPCRs and ligand-gated ion channels in serum-free
suspension cultures of several mammalian cell lines has
substantially facilitated purification efforts. Needless to say,
large-scale use of viral vectors always needs to take into
consideration the safety risks related to viral infectivity and
pathogenicity. The SFV vectors described in this review are
replication deficient. Additionally, the use of the second-
generation SFV helper vector (pSFV-Helper2) certifies the
production of only conditionally infectious particles due to
the presence of three point mutations in the SFV structural
genes [43]. Moreover, handling of SFV-infected cells and
other material has been demonstrated to be safe. Already
simple washes of cell cultures efficiently remove any
residual infectious particles [44]. Recombinant proteins
expressed from SFV vectors can therefore be safely
removed from the cell culture facility for activity assays
and downstream processing.
As for all research tools, technology improvements are
essential also for SFV vectors and their applications. Novel
less cytotoxic and temperature-sensitive mutant vectors
have recently been developed [44,45]. These should allow
a longer survival of host cells, which should be an advant-
age for establishing a prolonged expression phase with
potentially higher recombinant protein yields. The co-
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expression of GPCRs and G protein subunits is an interest-
ing application of the SFV system. It was shown that co-
infection of COS-7 cells with SFV particles carrying the a1B
adrenergic receptor and the Gaq, Gh2 and Gg2 subunits
enhanced significantly the functional coupling activity [46].
Co-expression could be a potentially attractive future
approach to stabilize GPCRs for purification and crystal-
lization.
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